More people surviving lung cancer

Nine years as an ovarian cancer “lifer” yields these tips for surviving and thriving when there’s no end of treatment ahead.
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
Ovarian cancer is the sixth most common cancer in women in the UK but the symptoms can be quite subtle, often leaving to a ...
TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...
The 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Ovarian cancer is challenging due to late-stage detection. Understanding genetic risk factors and family history can aid in ...
Higher pre- and postdiagnosis Alternate Mediterranean Diet (AMED) scores are associated with improved overall survival in patients with ovarian cancer.